Drugs / Eltoprazine
Eltoprazine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02439125 | May 2015 → Jun 2017 | Parkinson disease, drug-induced dyskinesia | Amarantus BioScience Holdings, Inc. | Unknown | Mixed |
| Phase 2 | NCT01266174 | Aug 2011 → Sep 2012 | cognitive impairment with or without cerebellar ataxia, schizophrenia | Amarantus BioScience Holdings, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eltoprazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266174 ↗ |
| Known as | DU-28853 | ChEMBL registry synonym — accepted as the source's own label CHEMBL282614 ↗ |
| Known as | Eltoprazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL282614 ↗ |
| Known as | Eltoprazine HCl | “Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks” NCT02439125 ↗ |
| Action | Activate | “Eltoprazine has agonist effects on both 5-HT1A and 5-HT1B receptors” NCT01266174 ↗ |
| Modality | Small molecule | — CHEMBL282614 ↗ |
| Route | Oral | “Comparison of eltoprazine, dosed orally, for 8 weeks” NCT01266174 ↗ |